Livelsberger Financial Advisory Anixa Biosciences Inc Call Options Transaction History
Livelsberger Financial Advisory
- $4.77 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ANIX
# of Institutions
60Shares Held
5.56MCall Options Held
21KPut Options Held
6.7K-
Vanguard Group Inc Valley Forge, PA1.39MShares$4.85 Million0.0% of portfolio
-
D.A. Davidson & Co.671KShares$2.34 Million0.02% of portfolio
-
Laird Norton Trust Company, LLC621KShares$2.16 Million0.26% of portfolio
-
Ubs Group Ag529KShares$1.84 Million0.0% of portfolio
-
Mission Wealth Management, LP510KShares$1.77 Million0.04% of portfolio
About Anixa Biosciences Inc
- Ticker ANIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 30,661,700
- Market Cap $107M
- Description
- Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the...